BOAN BIOTECH(06955),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

06955 BOAN BIOTECH

Not Yet Opened 12-12 16:08:09

8.950

+0.080

+0.90%

High9.000	Low8.740	Vol3.18M
Open8.900	D1 Closing8.870	Amplitude2.93%
Mkt Cap5.57B	Tradable Cap5.57B	Total Shares622.00M
T/O28.29M	T/O Rate0.51%	Tradable Shares622.33M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"06955","market":"HK","secType":"STK","nameCN":"BOAN BIOTECH","latestPrice":8.95,"timestamp":1765526889005,"preClose":8.87,"halted":0,"volume":3184000,"delay":0,"floatShares":622333694,"shares":622000000,"eps":0.15067015488988705,"marketStatus":"Not Yet Opened","change":0.08,"latestTime":"12-12 16:08:09","open":8.9,"high":9,"low":8.74,"amount":28289082,"amplitude":0.029312,"askPrice":8.96,"askSize":142200,"bidPrice":8.95,"bidSize":33000,"shortable":3,"etf":0,"ttmEps":0.06216662307818059,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765762200000},"marketStatusCode":0,"adr":0,"listingDate":1672329600000,"exchange":"SEHK","adjPreClose":8.87,"openAndCloseTimeList":[[1765503000000,1765512000000],[1765515600000,1765526400000]],"volumeRatio":0.8797232629042011,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06955","defaultTab":"news","newsList":[{"id":"2588008575","title":"Shandong Boan Biotechnology Co., Ltd. (HKG:6955) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?","url":"https://stock-news.laohu8.com/highlight/detail?id=2588008575","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588008575?lang=en_us&edition=fundamental","pubTime":"2025-12-04 07:02","pubTimestamp":1764802935,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotechnology (HKG:6955) has had a rough three months with its share price down 27%. However, stock...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6955/shandong-boan-biotechnology-shares/news/shandong-boan-biotechnology-co-ltd-hkg6955-stocks-been-slidi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6955/shandong-boan-biotechnology-shares/news/shandong-boan-biotechnology-co-ltd-hkg6955-stocks-been-slidi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","06955"],"gpt_icon":0},{"id":"1124932540","title":"Shandong Boan Biotechnology (06955) Releases Monthly Return for November 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1124932540","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124932540?lang=en_us&edition=fundamental","pubTime":"2025-12-03 16:55","pubTimestamp":1764752136,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotechnology Co., Ltd. (06955) submitted its monthly return for the month ended 30 November 2025. According to the document, the company’s registered share capital stood at RMB...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"gpt_icon":0},{"id":"1113894742","title":"BOAN BIOTECH (06955) Rises Nearly 7% in Early Trading as Aflibercept Ophthalmic Injection Solution Gains NMPA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1113894742","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113894742?lang=en_us&edition=fundamental","pubTime":"2025-11-27 09:38","pubTimestamp":1764207502,"startTime":"0","endTime":"0","summary":"BOAN BIOTECH (06955) surged nearly 7% in early trading, with gains moderating to 4.3% at the time of writing, reaching HK$10.91 and a turnover of HK$21.45 million. On November 26, BOAN BIOTECH...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955","BK1161"],"gpt_icon":0},{"id":"2586533002","title":"BRIEF-Shandong Boan Biotechnology Says Boyoujing Approved For Marketing In China By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2586533002","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586533002?lang=en_us&edition=fundamental","pubTime":"2025-11-26 18:17","pubTimestamp":1764152231,"startTime":"0","endTime":"0","summary":"BRIEF-Shandong Boan Biotechnology Says Boyoujing Approved For Marketing In China By NMPANov 26 (Reuters) - Shandong Boan Biotechnology Co Ltd 6955.HK:BOYOUJING APPROVED FOR MARKETING IN CHINA BY NMPAFurther company coverage: 6955.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nFWN3X20JL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955","BK1161"],"gpt_icon":0},{"id":"1175570142","title":"BOAN BIOTECH (06955): Aflibercept Ophthalmic Injection Solution Boyoujing® Approved for Launch in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1175570142","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175570142?lang=en_us&edition=fundamental","pubTime":"2025-11-26 17:50","pubTimestamp":1764150644,"startTime":"0","endTime":"0","summary":"BOAN BIOTECH (06955) announced that its self-developed Boyoujing® (aflibercept ophthalmic injection solution) has officially received marketing approval from China's National Medical Products...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06955"],"gpt_icon":0},{"id":"2586523028","title":"Shandong Boan Biotechnology Wins China Approval for Boyoujing Aflibercept Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2586523028","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586523028?lang=en_us&edition=fundamental","pubTime":"2025-11-26 17:42","pubTimestamp":1764150154,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotechnology Co. Ltd. has announced that China's National Medical Products Administration has granted marketing approval for its aflibercept intravitreous injection, Boyoujing. The product, a biosimilar to EYLEA, is indicated for the treatment of neovascular  age-related macular degeneration  and diabetic macular edema  in adults. Shandong Boan will collaborate with Ocumension Therapeutics to commercialize Boyoujing in the Chinese Mainland. The approval marks a significant milestone for the company as it seeks to expand access to ophthalmic treatments in China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the I","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL61ShLX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK1191","06955","01477"],"gpt_icon":0},{"id":"2586401230","title":"Shandong Boan Biotechnology - Boyoujing Approved for Marketing in China by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2586401230","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586401230?lang=en_us&edition=fundamental","pubTime":"2025-11-26 17:42","pubTimestamp":1764150143,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nFWN3X20JL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","06955"],"gpt_icon":0},{"id":"2586377412","title":"Ocumension Therapeutics Receives NMPA Approval to Market OT-702 in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2586377412","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586377412?lang=en_us&edition=fundamental","pubTime":"2025-11-26 17:21","pubTimestamp":1764148901,"startTime":"0","endTime":"0","summary":"Ocumension Therapeutics has received approval from the National Medical Products Administration  of China to market OT-702  for the treatment of neovascular  age-related macular degeneration  and diabetic macular edema  in adults. OT-702 was developed in partnership with Shandong Boan Biotechnology Co., Ltd. , and Ocumension holds the exclusive promotion and commercialization rights for the product in China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocumension Therapeutics published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on November 26, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL5FK2wB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","06955","BK1191","BK1161","BK1574"],"gpt_icon":0},{"id":"2585167841","title":"Luye Pharma Unit to Raise $150 Million via Boan-Linked Exchangeable Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2585167841","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585167841?lang=en_us&edition=fundamental","pubTime":"2025-11-21 09:48","pubTimestamp":1763689702,"startTime":"0","endTime":"0","summary":"Luye Pharma Group (HKG:2186) said a wholly owned unit has agreed to issue $150 million in exchangeable preference shares to an independent subscriber, according to a Friday Hong Kong bourse filing.The","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","BK1606","BK1191","06955","BK1161","02186"],"gpt_icon":0},{"id":"1181014719","title":"HK Stock Connect Shareholding Changes | November 12","url":"https://stock-news.laohu8.com/highlight/detail?id=1181014719","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181014719?lang=en_us&edition=fundamental","pubTime":"2025-11-12 08:38","pubTimestamp":1762907908,"startTime":"0","endTime":"0","summary":"As of November 11, 2025, data shows that HAO TIAN INTL (01341), REPT BATTERO (00666), and CTG DUTY-FREE (01880) recorded the largest increases in Stock Connect shareholding ratios, rising by 1.72%,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YR35.GBP","01347","IE00BZ08YT58.USD","LU1983299162.USD","BK1166","BK1554","BK1516","06955","BK1610","LU0588546209.SGD","BK1503","IE00BZ08YS42.EUR","SG9999003461.SGD","BK1518","BK1596","00902","BK1530","02402","BK1606","BK1241","BK1521","00763","00095","BK1546","LU2543165471.USD","BK1225","02162","HK0000252160.HKD","BK1568","BK1511","00187","LU1794554557.SGD","01282","BK1526","02050","LU0052750758.USD","BK1240","09995","LU1211504680.USD","BK1589","00666","02562","BK1169","BK1237","01773","02648","01071","09606","06616","BK1513","00119","LU1831875114.USD","06613","BK1205","BK1144","02587","BK1522","BK1506","LU0348825331.USD","BK1607","01053","BK1235","BK1138","01072","01341","LU0348735423.USD","MCHmain","06680","02255","03347","BK1564","BK1576","BK1555","LU1720050803.USD","03759","BK1515","BK1588","BK1129","BK1567","02828","LU0708995583.HKD","09696","BK1558","BK1125","BK1191","03800","LU2488822045.USD","02533","BK1556","BK1147","02465","LU0417516902.SGD","BK1504","00568","00956","02013","SG9999014674.SGD","BK1161","BK1224","BK1583","BK1582","BK1608","BK1116","BK1171","BK1560","02837","BK1163","BK1523","00874","BK1110","BK1170","BK1500","BK1228","BK1505","01880","02727","BK1183","BK1574","02865","HK0000252152.HKD","SG9999006597.SGD","BK1197","LU0320764599.SGD","02382","LU1969619763.USD","06869","00525","LU0326950275.SGD","03678","LU2328871848.SGD","09885","00189","IE00B29SXG58.USD","BK1149","BK1594","02631","01709","HK0000500386.USD","06865","BK1613","BK1148","BK1219","06682","LU0307460666.USD","BK1109","02208","09688","IE0034224299.USD","BK1236","03931","BK1202","BK1587","00968","BK1590","02068","03866","BK1529","BK1614","LU0417516738.SGD","01877","BK1141"],"gpt_icon":1},{"id":"1111308366","title":"BOAN BIOTECH (06955) Rises Over 4% in Afternoon Trading as Two Denosumab Injections Receive MHRA Approval in UK","url":"https://stock-news.laohu8.com/highlight/detail?id=1111308366","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111308366?lang=en_us&edition=fundamental","pubTime":"2025-11-10 14:32","pubTimestamp":1762756335,"startTime":"0","endTime":"0","summary":"BOAN BIOTECH (06955) surged more than 4% in afternoon trading, reaching HK$10.34 with a turnover of HK$31.69 million. The company announced that the UK Medicines and Healthcare products Regulatory...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955","BK1161"],"gpt_icon":0},{"id":"1155183044","title":"Shandong Boan Biotechnology (6955) Gains UK Acceptance for Two Denosumab Injections","url":"https://stock-news.laohu8.com/highlight/detail?id=1155183044","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155183044?lang=en_us&edition=fundamental","pubTime":"2025-11-07 12:23","pubTimestamp":1762489392,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotechnology Co., Ltd. (the “Company,” Stock Code: 6955) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has accepted its Marketing...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"gpt_icon":0},{"id":"1158198843","title":"BOAN BIOTECH (06955): UK Marketing Authorization Applications for Two Denosumab Injections Accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=1158198843","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158198843?lang=en_us&edition=fundamental","pubTime":"2025-11-07 12:14","pubTimestamp":1762488877,"startTime":"0","endTime":"0","summary":"BOAN BIOTECH (06955) announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has accepted its marketing authorization applications for two self-developed denosumab...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06955"],"gpt_icon":0},{"id":"2581249040","title":"UK MHRA Accepts Shandong Boan’s Marketing Applications for Two Denosumab Injections","url":"https://stock-news.laohu8.com/highlight/detail?id=2581249040","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581249040?lang=en_us&edition=fundamental","pubTime":"2025-11-07 12:07","pubTimestamp":1762488431,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotechnology Co. Ltd. has announced that its Marketing Authorisation Applications  for two denosumab injections, BA6101 and BA1102, have been accepted by the Medicines and Healthcare products Regulatory Agency  in the United Kingdom. BA6101 is a 60 mg injection for orthopedic indications, while BA1102 is a 120 mg injection for oncology indications. The acceptance marks an important regulatory milestone for the company as it pursues approvals in key global markets.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief on November 07, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL9xtGKq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955","BK1161"],"gpt_icon":0},{"id":"2581024607","title":"Shandong Boan Biotechnology - Marketing Authorisation Applications for Two Denosumab Injections Accepted in UK","url":"https://stock-news.laohu8.com/highlight/detail?id=2581024607","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581024607?lang=en_us&edition=fundamental","pubTime":"2025-11-07 12:02","pubTimestamp":1762488164,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nFWN3WI33U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06955","BK1161"],"gpt_icon":0},{"id":"1128685318","title":"Shandong Boan Biotechnology (06955) Announces No Change in Share Capital for October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1128685318","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128685318?lang=en_us&edition=fundamental","pubTime":"2025-11-05 16:44","pubTimestamp":1762332299,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotechnology (06955) released its monthly return for the period ended 31 October 2025, showing no modifications to its registered share capital. The total registered capital remained...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"gpt_icon":0},{"id":"1185832485","title":"Shandong Boan Biotechnology (6955) Completes Phase III Patient Enrollment for Nivolumab Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1185832485","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185832485?lang=en_us&edition=fundamental","pubTime":"2025-10-31 00:12","pubTimestamp":1761840758,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotechnology Co., Ltd. (the “Company”) announced the completion of patient enrollment for a Phase III clinical trial of its nivolumab injection, BA1104, in the People’s Republic of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955"],"gpt_icon":0},{"id":"1147000584","title":"BOAN BIOTECH (06955) Completes Patient Enrollment for Phase III Clinical Trial of Nivolumab in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1147000584","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147000584?lang=en_us&edition=fundamental","pubTime":"2025-10-30 21:36","pubTimestamp":1761831406,"startTime":"0","endTime":"0","summary":"BOAN BIOTECH (06955) announced that patient enrollment has been completed for the Phase III clinical trial of its self-developed BA1104 (nivolumab injection) in China. BA1104 is the first biosimilar...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955","BK1161"],"gpt_icon":0},{"id":"2579414247","title":"Shandong Boan Completes Phase III Trial Enrollment for Nivolumab Biosimilar in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2579414247","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579414247?lang=en_us&edition=fundamental","pubTime":"2025-10-30 21:02","pubTimestamp":1761829342,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotechnology Co. Ltd. has announced the completion of patient enrollment for a Phase III clinical trial of its nivolumab injection, code-named BA1104, in China. BA1104 is the first biosimilar of Opdivo in China to advance to a Phase III clinical trial. According to the company, Phase I trial results demonstrated that BA1104 is highly comparable to Opdivo in pharmacokinetics, safety, and immunogenicity, and these results have been published in the journal BioDrugs. The Phase III trial results have not yet been presented. Upon completion of the Phase III trial, the company may apply for approval of BA1104 for all indications that Opdivo has obtained in China, in accordance with national regulatory guidelines.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDLSdmR9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06955"],"gpt_icon":0},{"id":"1130889859","title":"HK Movers | HK's Biotech Shares Soar. Xuanzhu Bio up 19%; TransThera up 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1130889859","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130889859?lang=en_us&edition=fundamental","pubTime":"2025-10-22 10:09","pubTimestamp":1761098996,"startTime":"0","endTime":"0","summary":"Hong Kong’s biotech stocks rose on Wednesday.Xuanzhu Bio rose 19%; TransThera rose 13%; Boan Biotech rose 2%; CANbridge rose 1%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"069d3331287d7c7ffedd7cde87c41b57","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955","02617","02575"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.boan-bio.com","stockEarnings":[{"period":"1week","weight":-0.0519},{"period":"1month","weight":-0.1557},{"period":"3month","weight":-0.3024},{"period":"6month","weight":-0.3429},{"period":"1year","weight":-0.0067},{"period":"ytd","weight":-0.0407}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":-0.0351},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0872},{"period":"1year","weight":0.2736},{"period":"ytd","weight":0.295}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Shandong Boan Biotechnology Co Ltd is a China-based company primarily engaged in biopharmaceuticals. The Company is engaged in the development, production and commercialisation of therapeutic antibodies, focusing on the therapeutic areas of oncology, metabolism, autoimmunology and ophthalmology. The Company has three main technology platforms: a fully human antibody transgenic mouse and phage display technology platform, a bispecific T-cell Engager technology platform, and an antibody drug coupling (ADC) technology platform. The Company operates mainly in the domestic Chinese market and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.20669},{"month":2,"riseRate":0.666667,"avgChangeRate":0.021825},{"month":3,"riseRate":0.333333,"avgChangeRate":0.047525},{"month":4,"riseRate":0.666667,"avgChangeRate":0.053695},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.022243},{"month":6,"riseRate":0.333333,"avgChangeRate":0.003308},{"month":7,"riseRate":0.666667,"avgChangeRate":0.172102},{"month":8,"riseRate":0,"avgChangeRate":-0.097114},{"month":9,"riseRate":0.666667,"avgChangeRate":0.038827},{"month":10,"riseRate":0,"avgChangeRate":-0.109251},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.02386},{"month":12,"riseRate":0.333333,"avgChangeRate":0.001298}],"exchange":"SEHK","name":"BOAN BIOTECH","nameEN":"BOAN BIOTECH"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BOAN BIOTECH(06955),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BOAN BIOTECH(06955) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BOAN BIOTECH,06955,BOAN BIOTECH股票,BOAN BIOTECH股票老虎,BOAN BIOTECH股票老虎国际,BOAN BIOTECH行情,BOAN BIOTECH股票行情,BOAN BIOTECH股价,BOAN BIOTECH股市,BOAN BIOTECH股票价格,BOAN BIOTECH股票交易,BOAN BIOTECH股票购买,BOAN BIOTECH股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BOAN BIOTECH(06955),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BOAN BIOTECH(06955) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}